When will the launch time of bosutinib/bosutinib be determined in the country?

As of the end of January 2026, the original drug Bosutinib has not yet been officially launched in mainland China, and therefore has not yet entered the national drug registration system and medical insurance catalog. This means that domestic hospitals and pharmacies are temporarily unable to provide the drug directly through regular channels, and its price, reimbursement policy and unified specifications have not yet been announced. For some patients who need treatment with this drug, this situation increases the complexity of obtaining medication to a certain extent.

From the international market situation,Bosutinib has been approved and put into clinical use in many countries and regions, including many European countries, Switzerland, Turkey and other pharmaceutical markets. Most of the products sold in these regions are original research versions, and drug production, quality management and instruction manuals are relatively standardized. They have also become an important source for some patients with chronic myelogenous leukemia to learn about and come into contact with the drug through overseas channels. Different countries may have differences in packaging specifications, drug appearance and distribution prices, but their active ingredients and core pharmacological properties remain consistent.

At present, whether bosutinib will be introduced in China usually depends on many factors, including the company's registration application strategy, domestic treatment needs assessment and related regulatory processes. Judging from the previous experience in the introduction of other similar targeted drugs, it often takes a certain amount of time to complete the registration review and clinical data docking, so in the short term, overseas market information still needs to be used as a reference.

For patients, while paying attention to the progress of marketing, they should also pay more attention to the formality of the source of medication and the professional guidance of doctors. Obtaining information through legal and compliant medical channels can help reduce medication risks and prepare for possible future domestic launches.

Keyword tags: Bosutinib domestic launch time, Bosutinib launch in China, whether bosutinib will be included in medical insurance, bosutinib overseas version, CML targeted drug launch progress

Reference materials:https://www.drugs.com/mtm/bosutinib.html